$300mn To Be Funded By Novartis In European Biotherapeutics
The next-generation biotherapeutics will receive $300 million from Novartis, according to the company. To build a fully integrated, dedicated scientific environment to boost its...
Monkeypox Antiviral Clinical Trial Launches In United States
In the United States, adults and kids with monkeypox infection are now being enrolled in a Phase 3 clinical trial assessing the antiviral tecovirimat,...
Fresh Lumakras Lung Cancer Data From Amgen Fuel KRAS Dispute
Amgen is in the lead in a carefully watched race among KRAS inhibitors after winning a lung cancer randomised study. Now, the California drugmaker...
EU Authorities Outline A New Clinical Research Timeline
The European Commission (EC), Heads of Medicine Agencies (HMA), and European Medicines Agency (EMA) have released the 2022–2026 workplan for the programme Accelerating Clinical...
Dupixent Charts A Win Before The FDA Prurigo Nodularis Order
Dupixent, the immunology favourite developed by Sanofi and Regeneron Pharmaceuticals, is still on the rise. It has received back-to-back approvals this year for the...
FDA Advisors Help Drug Amylyx For ALS, Altering Prior Stance
A group of Food and Drug Administration advisers has recently come out in favour of a carefully monitored ALS drug, increasing the likelihood that...
With FDA Approval, Revance With Daxxify Will Rival Botox
Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...